HILLCO PARTNERS

Lobbying Income

$2.4M

Filings

140

Unique Clients

Active Period

2002–2026

Lobbying Income by Year

Registrant-reported income from clients on LDA filings

Year	Lobbying Income	Filings	Clients
2026	$120,000	3	1
2025	$50,000	2	1
2009	$120,000	16	5
2008	$300,000	40	11
2007	$460,000	24	10
2006	$480,000	17	10
2005	$340,000	12	8
2004	$440,000	15	8
2003	$100,000	10	5
2002	—	1	1

Largest clients by registrant-reported income

Client	Reported Income	Filings	Period
UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER	$490,000	14	2002–2008
AMGEN	$340,000	18	2003–2009
ALLERGAN	$310,000	15	2003–2009
EMPI INC	$270,000	10	2003–2008
WYETH PHARMACEUTICALS	$220,000	8	2003–2007
MCKESSON HEALTH SOLUTIONS	$215,000	12	2004–2008
AUSTIN STADCO LLC	$170,000	5	2025–2026
BIONICARE MEDICAL TECHNOLOGIES INC	$80,000	4	2006–2007
RESMED	$80,000	8	2008–2009
AMYLIN PHARMACEUTICALS	$60,000	5	2005–2007
SCHERING PLOUGH	$50,000	5	2008
MEDIMMUNE INC	$40,000	10	2004–2008
BAXTER HEALTHCARE	$40,000	3	2005–2006
TYCO HEALTHCARE GROUP LP DBA COVIDIEN	$30,000	4	2009
ASSOCIATION OF COMMUNITY CANCER CENTERS	$15,000	12	2004–2008
CYTOMEDIX, INC.	—	1	2008
SMITH & NEPHEW INC	—	6	2008–2009

Government entities explicitly identified as targets in LDA filings

Government Body	Filings
Centers For Medicare and Medicaid Services (CMS)	105
Health & Human Services, Dept of (HHS)	55
Agency for Healthcare Research & Quality (AHRQ)	25
Food & Drug Administration (FDA)	9
Office of Management & Budget (OMB)	9
White House Office	9
Natl Institutes of Health (NIH)	7
HOUSE OF REPRESENTATIVES	4
Centers For Disease Control & Prevention (CDC)	3
Council of Economic Advisers (CEA)	1

Most frequently reported lobbying issues

Issue Code	Description	Reports
Medicare/Medicaid	Medicare/Medicaid	131
Health Issues	Health Issues	19
Medical/Disease Research/Clinical Labs	Medical/Disease Research/Clinical Labs	5
Disaster Planning/Emergencies	Disaster Planning/Emergencies	5
Immigration	Immigration	5
Pharmacy	Pharmacy	1
Science/Technology	Science/Technology	1

HILLCO PARTNERS — Lobbying Disclosure | Poliscope